Dr. Morris on end points beyond survival achieved with 177Lu-PSMA-617 in VISION trial
The phase 3 VISION trial explored the PSMA-targeted therapy 177Lu-PSMA-617 (LuPSMA) in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer. Data presented at the 2021 ASCO Annual Meeting by lead study author Michael J. Morris, MD, showed that adding LuPSMA to standard of care (SOC) led to a nearly 40% reduction in the risk of death versus SOC alone. Adding LuPSMA to SOC also led to a 60% reduction in the risk of disease progression or death.
In this video, Morris, a medical oncologist and section head, Prostate Cancer, GU Oncology, Memorial Sloan Kettering Cancer Center, discusses other key end points reach with LuPSMA in the study, including time to symptomatic skeletal events, rate of PSA decline, and objective response rate (RECIST).
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
